Evaluation of primary prophylaxis with granulocyte colony-stimulating factor for epithelial ovarian cancer.
Eur J Gynaecol Oncol
; 35(1): 48-51, 2014.
Article
em En
| MEDLINE
| ID: mdl-24654461
ABSTRACT
PURPOSE:
Primary prophylaxis with G-CSF has been used to minimize myelosuppression caused by anticancer agents and to avoid severe neutropenia. The authors retrospectively examined the value of primary prophylaxis using granulocyte colony-stimulating factor (G-CSF) for epithelial ovarian cancer. MATERIALS ANDMETHODS:
From 2001 to 2010, 105 patients with ovarian cancer receiving chemotherapy in the present hospital were divided into two groups one received primary prophylaxis with G-CSF and the other did not receive it in compliance with the guidelines for G-CSF usage. The incidence of febrile neutropenia (FN), degree of neutropenia, frequency of G-CSF administration, number of days of hospitalization, progression-free survival (PFS), and overall survival (OS) were evaluated.RESULTS:
Neutrophils decreased almost equally and the length of hospitalization was not significantly lower between the groups. Five-year PFS or OS showed no significant difference either.CONCLUSIONS:
Primary prophylaxis with G-CSF in chemotherapy for epithelial ovarian cancer could be of low significance.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Fator Estimulador de Colônias de Granulócitos
/
Neoplasias Epiteliais e Glandulares
/
Fatores Imunológicos
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Eur J Gynaecol Oncol
Ano de publicação:
2014
Tipo de documento:
Article